It is currently trading at $6.82 a great deal lower than $8.11, the 50 day moving average and much lower than the 200 day moving average of $8.11. The 50 day moving average went down by -15.88% and the 200 day average was down $-1.29. 5,275 shares changed hands on Tuesday. Trading volume was down 97.88% under the stocks average daily volume.
Investors are more bullish on Adaptimmune Therapeutics plc – of late considering the motion in short interest. The stock had a fall in short interest between September 15, 2017 and September 29, 2017 of -30.73%. Short shares fell 295,796 over that timeframe. The short-interest ratio decreased to 2.0 and the short interest percentage is 0.00% as of September 29.
Here are a few substantial investment firms who have updated their positions. Vident Investment Advisory, LLC bolstered its position by buying 10,894 shares an increase of 4.7%. Vident Investment Advisory, LLC controls 243,535 shares with a value of $1,093,000. The total value of its holdings decreased 14.7%. As of quarter end Point72 Asset Management, L.p. had bought a total of 22,200 shares growing its position 4.2%. The value of the investment in ADAP decreased from $2,883,000 to $2,449,000 a change of 15.1% since the last quarter.
As of the end of the quarter Creative Planning had disposed of 500 shares trimming its stake by 1.2%. The value in dollars went from $182,000 to $328,000 increasing 80.2% quarter to quarter. Baillie Gifford & Co augmented its investment by buying 55,996 shares an increase of 18.5% in the quarter. Baillie Gifford & Co owns 358,320 shares valued at $2,935,000. The value of the position overall is up by 116.3%.
As of the last earnings report the EPS was $-0.99 and is projected to be $-0.99 for the current year with 93,519,000 shares presently outstanding. Analysts expect next quarter’s EPS will be $-0.25 and the next full year EPS is projected to be $-1.00.
Adaptimmune Therapeutics plc, launched on December 03, 2014, is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients..